Nina Herne
CEO
Virdings allé 32B, Uppsala
SE-754 50, Sweden
Phone: +46 (0) 70-7147457
Email: nina.herne@lidds.se
Anja Peters
CFO
Virdings allé 32B, Uppsala
SE-754 50, Sweden
Phone: +46 733 260000
Email: anja.peters@liddspharma.com
Lidds
LIDDS develops effective pharmaceutical products for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and effectively which means significantly fewer side effects compared with systemic treatment allowing a controlled, sustained and customized release of medication for up to six months.
Visitingadress: Virdings allé 32b, Uppsala
SE-754 50, Sweden. +46 00 44 55 66 info@liddspharma.com
Subscribe for news
Press releases
- 2021-07-06
LIDDS – subscription of warrants - 2021-06-02
LIDDS genomför en riktad nyemission av aktier och tillförs cirka 45 Mkr - 2021-06-02 LIDDS carry out a directed share issue of and is provided with approximately MSEK 45
- 2021-06-01 LIDDS Announces Appointment of Jenni Björnulfson as New Chief Financial Officer
- 2021-06-02 LIDDS genomför en riktad nyemission av aktier och tillförs cirka 45 Mkr
- 2021-06-02 LIDDS carry out a directed share issue of and is provided with approximately MSEK 45
- 2021-06-01 LIDDS Announces Appointment of Jenni Björnulfson as New Chief Financial Officer
- 2021-05-27 LIDDS avser att genomföra en riktad nyemission av aktier om cirka 45 Mkr
LIDDS AB (publ) Org No.: 556580-2856, Virdings allé 32B, 754 50 UPPSALA, www.liddspharma.com
